Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Broome

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
Lancet (London, England)|October 1, 2023
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trialCatherine M Broome, Vickie McDonald, Yoshitaka Miyakawa, et al.
Revue Medicale Suisse|April 1, 2009
[Children born with a cleft: treatment at the CHUV in Lausanne]J Hohlfeld, A de Buys Roessingh, G Herzog, et al.
Cancer Genetics and Cytogenetics|February 12, 1999
Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanomaM A Nelson, M E Ariza, J M Yang, et al.
Psychological Medicine|July 29, 2014
Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra high riskG Modinos, P Allen, M Frascarelli, et al.
European Journal of Haematology|November 20, 2022
Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA studyAlexander Röth, Catherine M Broome, Wilma Barcellini, et al.
The New England Journal of Medicine|April 7, 2021
Sutimlimab in Cold Agglutinin DiseaseAlexander Röth, Wilma Barcellini, Shirley D'Sa, et al.
Eclinicalmedicine|August 8, 2024
Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extensionAlexander Röth, Catherine M Broome, Wilma Barcellini, et al.
The Journal of Trauma and Acute Care Surgery|May 1, 2024
Every minute matters: Improving outcomes for penetrating trauma through prehospital advanced resuscitative careJuan Duchesne, Bryant J McLafferty, Jacob M Broome, et al.
Expert Review of Clinical Immunology|April 29, 2025
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseasesKelly G Gwathmey, Catherine M Broome, Matthias Goebeler, et al.
Haematologica|February 17, 2022
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up resultsAlexander Roth, Wilma Barcellini, Shirley D'Sa, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
Lancet (London, England)|October 1, 2023
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trialCatherine M Broome, Vickie McDonald, Yoshitaka Miyakawa, et al.
Revue Medicale Suisse|April 1, 2009
[Children born with a cleft: treatment at the CHUV in Lausanne]J Hohlfeld, A de Buys Roessingh, G Herzog, et al.
Cancer Genetics and Cytogenetics|February 12, 1999
Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanomaM A Nelson, M E Ariza, J M Yang, et al.
Psychological Medicine|July 29, 2014
Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra high riskG Modinos, P Allen, M Frascarelli, et al.
European Journal of Haematology|November 20, 2022
Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA studyAlexander Röth, Catherine M Broome, Wilma Barcellini, et al.
The New England Journal of Medicine|April 7, 2021
Sutimlimab in Cold Agglutinin DiseaseAlexander Röth, Wilma Barcellini, Shirley D'Sa, et al.
Eclinicalmedicine|August 8, 2024
Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extensionAlexander Röth, Catherine M Broome, Wilma Barcellini, et al.
The Journal of Trauma and Acute Care Surgery|May 1, 2024
Every minute matters: Improving outcomes for penetrating trauma through prehospital advanced resuscitative careJuan Duchesne, Bryant J McLafferty, Jacob M Broome, et al.
Expert Review of Clinical Immunology|April 29, 2025
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseasesKelly G Gwathmey, Catherine M Broome, Matthias Goebeler, et al.
Haematologica|February 17, 2022
Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up resultsAlexander Roth, Wilma Barcellini, Shirley D'Sa, et al.
Pageof 14